Ghanshyam Teli

Scopus Publications

Therapeutic Approaches to Treat SARS-CoV-2
Lekhnath Sharma, Neelesh Maheshwari, Nupur Maheshwari, Ghanshyam Teli, Venkatesh Chelvam
Chemmedchem, 2026
Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), also known as COVID‐19, spread across the globe, leading to a pandemic. Initially, the drug remdesivir is approved by the FDA for the treatment of SARS‐CoV‐2. Significant efforts have been directed toward epidemiology of the SARS‐CoV‐2 virus to discover potential drug targets that may contribute to the development of effective prevention and treatment strategies. The structure and functions of SARS‐CoV‐2 proteins that may be potential drug targets, including the spike protein, main protease, papain‐like protease, RNA‐dependent RNA polymerase, host proteins like angiotensin‐converting enzyme 2, and transmembrane protease and serine 2, have been thoroughly studied. Biological screening platforms and repurposing have resulted in the discovery of drugs such as nirmatrelvir‐ritonavir (Paxlovid), remdesivir (Veklury), molnupiravir (Lagevrio), anakinra (Kineret), vilobelimab (Gohibic), baricitinib (Olumiant), and tocilizumab (Actemra). The present analysis provides details on the pathogenesis, prevention, diagnosis, clinical characteristics, and potential treatment options currently available worldwide.
Design strategies, structural insights, and biological potential of amyloid-beta inhibitors in Alzheimer’s disease
Mridul Guleria, Arprita Malhan, Ghanshyam Teli, Nidhi Bisht, Subheet Kumar Jain
Molecular Diversity, 2026
Explanatory review on DDR inhibitors: their biological activity, synthetic route, and structure–activity relationship
Sindhuja Sengupta, Lalmohan Maji, Pronoy Kanti Das, Ghanshyam Teli, Mrinmoy Nag, Nirmalya Khan, Mridul Haque, Gurubasavaraja Swamy Purawarga Matada
Molecular Diversity, 2025
Design, Synthesis, and Molecular Profiling of Pyrimidine-Furan Derivatives Targeting EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S in NSCLC: In Vitro and In Silico Evaluation
Rohit Pal, Gurubasavaraja Swamy Purawarga Matada, Ghanshyam Teli, Md Jawaid Akhtar, Bhupinder Kumar
Chemistry and Biodiversity, 2025
Epidermal growth factor receptor (EGFR) mutations, especially in non–small cell lung cancer (NSCLC), present significant challenges to targeted therapies due to acquired resistance. This study reports the synthesis and evaluation of a series of 4‐(2‐substituted‐6‐(furan‐2‐yl)pyrimidin‐4‐yl)‐substituted phenyl derivatives as potential anticancer agents. The compounds were screened using MTT and brine shrimp lethality assays, identifying R2 , R10 , and R12 as the most potent against NSCLC cell lines, particularly NCI‐H522 and NCI‐H1975. Compound R12 was most potent and selective against NCI‐H522, with an IC 50 value of 0.95 ± 0.02 µM as compared to standard afatinib (IC 50 = 1.86 ± 0.22 µM). EGFR inhibition assays confirmed R12 effectiveness with IC 50 values of 1.62 ± 0.15 µM, 0.49 ± 0.23 µM, and 0.98 ± 0.02 µM against EGFR WT , EGFR T790M , and EGFR L858R/T790M/C797S , respectively. The compound R12 led to the cell cycle arrest in the G2/M and S phase of NCI‐H522 cells with an increase in apoptosis. Molecular docking studies showed R12 high binding affinity (Δ G = −10.2 kcal/mol for EGFR WT ; K i = 32.73 nM) and significant interactions with key amino acids in the active site. Molecular dynamics simulations demonstrated stable protein–ligand interactions with low RMSD (0.17–0.27 nm) and significant eigenvalue (1.706 × 10 −4 ). Compound R12 also exhibited antioxidant properties against DPPH (IC 50 = 12.11 ± 8.96 µM) and H 2 O 2 (IC 50 = 8.89 ± 1.72 µM). Furthermore, DFT analysis and ADMET predictions indicated that R12 possesses favorable physiochemical and pharmacokinetic properties, suggesting high bioavailability and minimal toxicity. These findings emphasize R12 as a promising lead for further preclinical investigation in overcoming EGFR mutations, including the challenging triple mutation.
Integrated Computational and Experimental Insights Into MEK1/2 Inhibitors: Structural Validation, Docking, ADMET, Molecular Dynamics, and Anticancer Evaluation
Rohit Pal, Gurubasavaraja Swamy Purawarga Matada, Ghanshyam Teli
Chemistry and Biodiversity, 2025
This study explores the therapeutic potential of novel MEK1/2 inhibitors targeting the MAPK pathway, emphasizing their critical role in cancer progression. An integrated computational approach, including molecular docking, pharmacophore modeling, molecular dynamics simulations, and DFT analysis, was employed to evaluate the binding affinity, stability, and pharmacological properties of FDA‐approved and experimental compounds. Structural validation of MEK1 (PDB ID: 1S9J) and MEK2 (PDB ID: 1S9I) revealed z‐scores of −6.89 and −7.13, respectively, with 90.6% and 86.7% of residues in the most favored regions, confirming the reliability of the protein models. Docking studies identified RO5126766 as a lead compound, exhibiting binding energies of −10.1 kcal/mol with MEK1 and −9.5 kcal/mol with MEK2. Molecular dynamics simulations further demonstrated the stability of the RO5126766–MEK1 and RO5126766–MEK2 complexes, with RMSD values ranging from 0.95 to 4.22 Å. The in vitro anticancer assays highlighted the exceptional potency of RO5126766, with IC50 values of 12.87 ± 98.36 nM against MCF‐7 (hormone receptor‐positive breast cancer), 15.08 ± 94.36 nM against MDA‐MB‐231 (triple‐negative breast cancer), and 60.89 ± 70.58 nM against A549 (lung cancer). ADMET analysis confirmed high gastrointestinal absorption, favorable drug‐likeness, and lack of blood‐brain barrier permeability. In addition, DFT studies indicated an optimal HOMO–LUMO energy gap (0.15816 eV), chemical hardness (0.16189 eV), and strong molecular interactions corroborated by MEP analysis. Collectively, these findings establish RO5126766 as a potent and selective MEK1/2 inhibitor, demonstrating significant potential as a targeted therapeutic agent for aggressive and treatment‐resistant cancers.
Design, synthesis, and biological evaluation of novel 4-(4-ethoxyphenyl)-6-(substituted-phenyl)pyrimidin-2-amine/thiol/hydroxy derivatives as EGFRWT and EGFRT790M inhibitors targeting NSCLC: In-vitro and in-silico exploration
Rohit Pal, Gurubasavaraja Swamy Purawarga Matada, Ghanshyam Teli, Viney Chawla, Pooja A. Chawla
Journal of Molecular Structure, 2025
Repositioning of drugs in non-small cell lung cancer: Old weapons for a new war
Drug Repurposing Novel Therapeutic Avenues and Innovations in Healthcare, 2025
Recent advancements in mechanistic research, therapeutic potential, and structure-activity relationships of aurora kinase inhibitors in cancer therapies
Ghanshyam Teli, Lalmohan Maji, Rohit Pal, Neelesh Maheshwari, Gurubasavaraja Swamy Purawarga Matada, Pooja A. Chawla, Viney Chawla
Bioorganic Chemistry, 2025
Exploring tetrazole chemistry: synthetic techniques, structure–activity relationship, and pharmacological insights in antimicrobial and anticancer therapy
Lalmohan Maji, Ghanshyam Teli, Rohit Pal, Neelesh Maheshwari, Praveen Kumar Soni, Gurubasavaraja Swamy Purawarga Matada, Mahendra Singh Rathore, Venkatesan Saravanan, Kathiravan Muthukumaradoss
Frontiers in Chemistry, 2025
Tetrazoles are nitrogen-rich heterocycles that have attracted interest because of their numerous applications in pharmaceutical and medicinal chemistry. Four nitrogen atoms and one carbon atom make up these five-membered rings, which have special physicochemical and electrical characteristics, including acidity, resonance stabilization, and aromaticity. This article highlights the structure, spectroscopic characteristics, and physical and chemical characteristics of tetrazoles. It also describes how overlapping mechanisms, such as DNA replication inhibition, protein synthesis disruption, and oxidative stress induction, as well as similar therapeutic targets, enable inhibitors to serve as both antibacterial and anticancer agents. Tetrazole moieties have been fused with a range of pharmacophores, such as indoles, pyrazoles, quinolines, and pyrimidines, yielding fused derivatives that display substantial inhibitory activity against bacterial, fungal, and cancer cell lines, with certain compounds exhibiting efficacy comparable to or exceeding that of established therapeutic agents. The rational design of more efficacious tetrazole-based therapies is facilitated by structure–activity relationship analysis, which further highlights significant functional groups and scaffolds that contribute to increasing activity. We investigate the relationship between microbial inhibition and anticancer efficacy, opening up new avenues for the creation of multifunctional therapeutic agents. We hope that this study will offer significant guidance and serve as a valued resource for medicinal and organic researchers working on drug development and discovery in multifunctional therapeutics. The review involves a thorough investigation of tetrazole in recent years.
Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship
Lalmohan Maji, Sindhuja Sengupta, Gurubasavaraja Swamy Purawarga Matada, Ghanshyam Teli, Gourab Biswas, Pronoy Kanti Das, Manjunatha Panduranga Mudgal
Molecular Diversity, 2024
Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure–activity relationship
Rohit Pal, Gurubasavaraja Swamy Purawarga Matada, Ghanshyam Teli, Moumita Saha, Rajiv Patel
Bioorganic Chemistry, 2024
An updated literature on BRAF inhibitors (2018–2023)
Lalmohan Maji, Ghanshyam Teli, Nulgumnalli Manjunathaiah Raghavendra, Sindhuja Sengupta, Rohit Pal, Abhishek Ghara, Gurubasavaraja Swamy Purawarga Matada
Molecular Diversity, 2024
Synthetic product-based approach toward potential antileishmanial drug development
Rohit Pal, Ghanshyam Teli, Md Jawaid Akhtar, Gurubasavaraja Swamy Purawarga Matada
European Journal of Medicinal Chemistry, 2024
An outlook of docking analysis and structure-activity relationship of pyrimidine-based analogues as EGFR inhibitors against non-small cell lung cancer (NSCLC)
Rohit Pal, Ghanshyam Teli, Sindhuja Sengupta, Lalmohan Maji, Gurubasavaraja Swamy Purawarga Matada
Journal of Biomolecular Structure and Dynamics, 2024
Explanatory review on pyrimidine/fused pyrimidine derivatives as anticancer agents targeting Src kinase
Ghanshyam Teli, Rohit Pal, Lalmohan Maji, Gurubasavaraja Swamy Purawarga Matada, Sindhuja Sengupta
Journal of Biomolecular Structure and Dynamics, 2024
Designing strategies, structural activity relationship and biological activity of recently developed nitrogen containing heterocyclic compounds as epidermal growth factor receptor tyrosinase inhibitors
Rohit Pal, Ghanshyam Teli, Gurubasavaraja Swamy Purawarga Matada, Prasad Sanjay Dhiwar
Journal of Molecular Structure, 2023
The role of natural anti-parasitic guided development of synthetic drugs for leishmaniasis
Rohit Pal, Ghanshyam Teli, Md Jawaid Akhtar, Gurubasavaraja Swamy Purawarga Matada
European Journal of Medicinal Chemistry, 2023
Medicinal Chemistry Perspectives on Recent Advances in Src Kinase Inhibitors as a Potential Target for the Development of Anticancer Agents: Biological Profile, Selectivity, Structure-Activity Relationship
Ghanshyam Teli, Rohit Pal, Lalmohan Maji, Sindhuja Sengupta, Nulgumnalli Manjunathaiah Raghavendra, Gurubasavaraja Swamy Purawarga Matada
Chemistry and Biodiversity, 2023
Nitrogen-Containing Heterocyclic Scaffolds as EGFR Inhibitors: Design Approaches, Molecular Docking, and Structure-Activity Relationships
Rohit Pal, Ghanshyam Teli, Gurubasavaraja Swamy Purawarga Matada, Prasad Sanjay Dhiwar
Chemistryselect, 2023
SYNTHESIS, CHARACTERIZATION, IN VITRO ANTIMICROBIAL AND ANTI-INFLAMMATORY EVALUATIONS OF {5’-(SUBSTITUTED ARYL)-2-FURANYL}-3,4-DIHYDRO-1H-PYRIMIDINE-2-ONE DERIVATIVES
, Munendra M. Varshney, Pooja A. Chawla, Ghanshyam Teli, Asif Hussain
Indian Drugs, 2023
Nitrogen-containing Heterocyclic Derivatives of 1,3-Thiazolidine-2,4- Diones as Dual Anti-inflammatory and Anti-oxidant Agents and their Docking Studies
Priyanka Srivastava, Ghanshyam Teli, Pooja A. Chawla
Letters in Drug Design and Discovery, 2023
Exploring the Potential of Substituted 4-Thiazolidinone Derivatives in the Treatment of Breast Cancer: Synthesis, Biological Screening and In Silico Studies
Ghanshyam Teli, Priyanka Sharma, Pooja A. Chawla
Polycyclic Aromatic Compounds, 2023
Exploration of Antioxidant, Anti-inflammatory and Anticancer Potential of Substituted 4-Thiazolidinone Derivatives: Synthesis, Biological Evaluation and Docking Studies
Archna, Pooja A. Chawla, Ghanshyam Teli, Shelly Pathania, Shamsher Singh, Vandana Srivastava
Polycyclic Aromatic Compounds, 2023
Designing Studies in Pharmaceutical and Medicinal Chemistry
N. M. Raghavendra, B. R. Prashantha Kumar, Pujan Sasmal, Ghanshyam Teli, Rohit Pal, P. M. Gurubasavaraja Swamy, B. Sajeev Kumar
Quintessence of Basic and Clinical Research and Scientific Publishing, 2023
Nano-biosensors from Agriculture to Nextgen Diagnostic Tools
Pooja A. Chawla, Deepika Sharma, Ghanshyam Teli, Komal Gupta, Garima Bansal, Ghanshyam Das Gupta
Current Nanomaterials, 2022
An Insight into Synthetic Strategies and Recent Developments of Dihydrofolate Reductase Inhibitors
Pooja Chawla, Ghanshyam Teli, Rupinder Kaur Gill, Raj Kumar Narang
Chemistryselect, 2021
Hybridization of Imidazole with Various Heterocycles in Targeting Cancer: A Decade's Work
Ghanshyam Teli, Pooja A. Chawla
Chemistryselect, 2021

RECENT SCHOLAR PUBLICATIONS

Therapeutic Approaches to Treat SARS‐CoV‐2
L Sharma, N Maheshwari, N Maheshwari, G Teli, V Chelvam
ChemMedChem 21 (4), e202500387 , 2026
2026
Design strategies, structural insights, and biological potential of amyloid-beta inhibitors in Alzheimer’s disease
M Guleria, A Malhan, G Teli, N Bisht, SK Jain
Molecular Diversity 30 (1), 273-298 , 2026
2026
Citations: 1
Exploring tetrazole chemistry: synthetic techniques, structure–activity relationship, and pharmacological insights in antimicrobial and anticancer therapy
L Maji, G Teli, R Pal, N Maheshwari, PK Soni, GSP Matada, MS Rathore, ...
Frontiers in Chemistry 13, 1700143 , 2025
2025
Design, Synthesis, and Molecular Profiling of Pyrimidine‐Furan Derivatives Targeting EGFR WT , EGFR T790M , and EGFR L858R/T790M/C797S in NSCLC: In Vitro …
R Pal, GSP Matada, G Teli, MJ Akhtar, B Kumar
Chemistry & Biodiversity 22 (9), e202500549 , 2025
2025
Citations: 1
Integrated computational and experimental insights into MEK1/2 inhibitors: structural validation, docking, ADMET, molecular dynamics, and anticancer evaluation
R Pal, GSP Matada, G Teli
Chemistry & Biodiversity 22 (7), e202402907 , 2025
2025
Citations: 2
Design, synthesis, and biological evaluation of novel 4-(4-ethoxyphenyl)-6-(substituted-phenyl) pyrimidin-2-amine/thiol/hydroxy derivatives as EGFRWT and EGFRT790M inhibitors …
R Pal, GSP Matada, G Teli, V Chawla, PA Chawla
Journal of Molecular Structure 1327, 141227 , 2025
2025
Citations: 9
Explanatory review on DDR inhibitors: their biological activity, synthetic route, and structure–activity relationship
S Sengupta, L Maji, PK Das, G Teli, M Nag, N Khan, M Haque, ...
Molecular Diversity, 1-31 , 2025
2025
Citations: 3
Recent advancements in mechanistic research, therapeutic potential, and structure-activity relationships of aurora kinase inhibitors in cancer therapies
G Teli, L Maji, R Pal, N Maheshwari, GSP Matada, PA Chawla, V Chawla
Bioorganic Chemistry 154, 107976 , 2025
2025
Citations: 7
An outlook of docking analysis and structure-activity relationship of pyrimidine-based analogues as EGFR inhibitors against non-small cell lung cancer (NSCLC)
R Pal, G Teli, S Sengupta, L Maji, GS Purawarga Matada
Journal of Biomolecular Structure and Dynamics 42 (18), 9795-9811 , 2024
2024
Citations: 32
Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship
L Maji, S Sengupta, GS Purawarga Matada, G Teli, G Biswas, PK Das, ...
Molecular Diversity 28 (6), 4467-4513 , 2024
2024
Citations: 13
Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure …
R Pal, GSP Matada, G Teli, M Saha, R Patel
Bioorganic Chemistry 152, 107696 , 2024
2024
Citations: 21
An updated literature on BRAF inhibitors (2018–2023)
L Maji, G Teli, NM Raghavendra, S Sengupta, R Pal, A Ghara, ...
Molecular Diversity 28 (4), 2689-2730 , 2024
2024
Citations: 25
Explanatory review on pyrimidine/fused pyrimidine derivatives as anticancer agents targeting Src kinase
G Teli, R Pal, L Maji, GS Purawarga Matada, S Sengupta
Journal of Biomolecular Structure and Dynamics 42 (3), 1582-1614 , 2024
2024
Citations: 12
Synthetic product-based approach toward potential antileishmanial drug development
R Pal, G Teli, MJ Akhtar, GSP Matada
European Journal of Medicinal Chemistry 263, 115927 , 2024
2024
Citations: 31
Designing strategies, structural activity relationship and biological activity of recently developed nitrogen containing heterocyclic compounds as epidermal growth factor …
R Pal, G Teli, GSP Matada, PS Dhiwar
Journal of Molecular Structure 1291, 136021 , 2023
2023
Citations: 59
The role of natural anti-parasitic guided development of synthetic drugs for leishmaniasis
R Pal, G Teli, MJ Akhtar, GSP Matada
European Journal of Medicinal Chemistry 258, 115609 , 2023
2023
Citations: 30
Designing studies in pharmaceutical and medicinal chemistry
NM Raghavendra, BRP Kumar, P Sasmal, G Teli, R Pal, ...
The Quintessence of Basic and Clinical Research and Scientific Publishing … , 2023
2023
Citations: 5
Medicinal Chemistry Perspectives on Recent Advances in Src Kinase Inhibitors as a Potential Target for the Development of Anticancer Agents: Biological Profile, Selectivity …
G Teli, R Pal, L Maji, S Sengupta, NM Raghavendra, GSP Matada
Chemistry & Biodiversity 20 (9), e202300515 , 2023
2023
Citations: 16
Exploring the Potential of Substituted 4-Thiazolidinone Derivatives in the Treatment of Breast Cancer: Synthesis, Biological Screening and In Silico Studies
G Teli, P Sharma, PA Chawla
Polycyclic Aromatic Compounds 43 (7), 6202-6234 , 2023
2023
Citations: 15
Nitrogen‐containing heterocyclic scaffolds as EGFR inhibitors: design approaches, molecular docking, and structure‐activity relationships
R Pal, G Teli, G Swamy Purawarga Matada, P Sanjay Dhiwar
ChemistrySelect 8 (26), e202301200 , 2023
2023
Citations: 22

MOST CITED SCHOLAR PUBLICATIONS

Designing strategies, structural activity relationship and biological activity of recently developed nitrogen containing heterocyclic compounds as epidermal growth factor …
R Pal, G Teli, GSP Matada, PS Dhiwar
Journal of Molecular Structure 1291, 136021 , 2023
2023
Citations: 59
Hybridization of imidazole with various heterocycles in targeting cancer: a decade's work
G Teli, PA Chawla
ChemistrySelect 6 (19), 4803-4836 , 2021
2021
Citations: 40
Exploration of antioxidant, anti-inflammatory and anticancer potential of substituted 4-thiazolidinone derivatives: synthesis, biological evaluation and docking studies
Archna, PA Chawla, G Teli, S Pathania, S Singh, V Srivastava
Polycyclic Aromatic Compounds 43 (1), 597-618 , 2023
2023
Citations: 36
An insight into synthetic strategies and recent developments of dihydrofolate reductase inhibitors
P Chawla, G Teli, RK Gill, RK Narang
ChemistrySelect 6 (43), 12101-12145 , 2021
2021
Citations: 35
An outlook of docking analysis and structure-activity relationship of pyrimidine-based analogues as EGFR inhibitors against non-small cell lung cancer (NSCLC)
R Pal, G Teli, S Sengupta, L Maji, GS Purawarga Matada
Journal of Biomolecular Structure and Dynamics 42 (18), 9795-9811 , 2024
2024
Citations: 32
Synthetic product-based approach toward potential antileishmanial drug development
R Pal, G Teli, MJ Akhtar, GSP Matada
European Journal of Medicinal Chemistry 263, 115927 , 2024
2024
Citations: 31
The role of natural anti-parasitic guided development of synthetic drugs for leishmaniasis
R Pal, G Teli, MJ Akhtar, GSP Matada
European Journal of Medicinal Chemistry 258, 115609 , 2023
2023
Citations: 30
An updated literature on BRAF inhibitors (2018–2023)
L Maji, G Teli, NM Raghavendra, S Sengupta, R Pal, A Ghara, ...
Molecular Diversity 28 (4), 2689-2730 , 2024
2024
Citations: 25
Nitrogen‐containing heterocyclic scaffolds as EGFR inhibitors: design approaches, molecular docking, and structure‐activity relationships
R Pal, G Teli, G Swamy Purawarga Matada, P Sanjay Dhiwar
ChemistrySelect 8 (26), e202301200 , 2023
2023
Citations: 22
Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure …
R Pal, GSP Matada, G Teli, M Saha, R Patel
Bioorganic Chemistry 152, 107696 , 2024
2024
Citations: 21
Medicinal Chemistry Perspectives on Recent Advances in Src Kinase Inhibitors as a Potential Target for the Development of Anticancer Agents: Biological Profile, Selectivity …
G Teli, R Pal, L Maji, S Sengupta, NM Raghavendra, GSP Matada
Chemistry & Biodiversity 20 (9), e202300515 , 2023
2023
Citations: 16
Exploring the Potential of Substituted 4-Thiazolidinone Derivatives in the Treatment of Breast Cancer: Synthesis, Biological Screening and In Silico Studies
G Teli, P Sharma, PA Chawla
Polycyclic Aromatic Compounds 43 (7), 6202-6234 , 2023
2023
Citations: 15
Nano-biosensors from agriculture to Nextgen diagnostic tools
D Sharma, G Teli, K Gupta, G Bansal, GD Gupta, PA Chawla
Current Nanomaterials 7 (2), 110-138 , 2022
2022
Citations: 15
Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship
L Maji, S Sengupta, GS Purawarga Matada, G Teli, G Biswas, PK Das, ...
Molecular Diversity 28 (6), 4467-4513 , 2024
2024
Citations: 13
< p style=
R Pal, G Teli, B Sharma, B Kumar, PA Chawla
Pharmaspire 13, 21-27 , 2021
2021
Citations: 13
Explanatory review on pyrimidine/fused pyrimidine derivatives as anticancer agents targeting Src kinase
G Teli, R Pal, L Maji, GS Purawarga Matada, S Sengupta
Journal of Biomolecular Structure and Dynamics 42 (3), 1582-1614 , 2024
2024
Citations: 12
Design, synthesis, and biological evaluation of novel 4-(4-ethoxyphenyl)-6-(substituted-phenyl) pyrimidin-2-amine/thiol/hydroxy derivatives as EGFRWT and EGFRT790M inhibitors …
R Pal, GSP Matada, G Teli, V Chawla, PA Chawla
Journal of Molecular Structure 1327, 141227 , 2025
2025
Citations: 9
Recent advancements in mechanistic research, therapeutic potential, and structure-activity relationships of aurora kinase inhibitors in cancer therapies
G Teli, L Maji, R Pal, N Maheshwari, GSP Matada, PA Chawla, V Chawla
Bioorganic Chemistry 154, 107976 , 2025
2025
Citations: 7
Nitrogen-containing heterocyclic derivatives of 1, 3-thiazolidine-2, 4-diones as Dual Anti-inflammatory and anti-oxidant agents and their docking studies
P Srivastava, G Teli, PA Chawla
Letters in Drug Design & Discovery 20 (7), 894-915 , 2023
2023
Citations: 7
Designing studies in pharmaceutical and medicinal chemistry
NM Raghavendra, BRP Kumar, P Sasmal, G Teli, R Pal, ...
The Quintessence of Basic and Clinical Research and Scientific Publishing … , 2023
2023
Citations: 5

Ghanshyam Teli

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS